FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048690244> ?p ?o ?g. }

• W3048690244 endingPage "1669.e2" @default.
• W3048690244 startingPage "1661" @default.
• W3048690244 abstract "Background & AimsProgression of stages 2 and 3 acute kidney injury (AKI) in cirrhosis has not been characterized adequately. Patients with higher stages of AKI are believed to have worse outcomes. We assessed outcomes and factors associated with stages 2 and 3 AKI in patients with cirrhosis in the North American Consortium for the Study of End-stage Liver Disease cohort.MethodsWe collected data from 2297 hospitalized patients with cirrhosis and ascites from December 2011 through February 2017. Our final analysis included 760 patients who developed AKI per the International Ascites Club 2015 definition (419 with maximum stage 1 and 341 with maximum stage 2 or 3; 63% male; mean age, 58 y). We compared demographic features, laboratory values, AKI treatment response, and survival between patients with maximum stage 1 vs patients with stage 2 or 3 AKI.ResultsPatients with stage 2 or 3 AKI had higher Model for End-Stage Liver Disease scores (25.9 ± 7.3) than patients with stage 1 AKI (21.9 ± 7.5) (P < .0001). More patients fulfilled systemic inflammatory response syndrome criteria on admission, and more developed a second nosocomial infection (P < .05 for both comparisons). More patients with stage 2 or 3 AKI also had progression of AKI and required dialysis and admission into intensive care units when compared to stage 1 AKI patients (P < .0001 for both). A lower proportion of patients with stage 2 or 3 AKI survived their hospital stay (80% vs 99% with stage 1 AKI; P < .0001), or survived for 30 days without a liver transplant (56% vs 81%; P < .0001). The development of stage 2 or 3 AKI was associated with a higher Model for End-Stage Liver Disease score at the time of admission (P < .0001), presence of systemic inflammatory response on admission (P = .039), and second infection (P < .0001).ConclusionsBased on an analysis of data from the North American Consortium for the Study of End-stage Liver Disease cohort, we found that patients with cirrhosis and more advanced liver disease, as well as a second infection, are more likely to develop stages 2 or 3 AKI, with a progressive course associated with decreased 30-day transplant-free survival. Prevention of AKI progression in patients with cirrhosis and stage 2 or 3 AKI might improve their outcomes. Progression of stages 2 and 3 acute kidney injury (AKI) in cirrhosis has not been characterized adequately. Patients with higher stages of AKI are believed to have worse outcomes. We assessed outcomes and factors associated with stages 2 and 3 AKI in patients with cirrhosis in the North American Consortium for the Study of End-stage Liver Disease cohort. We collected data from 2297 hospitalized patients with cirrhosis and ascites from December 2011 through February 2017. Our final analysis included 760 patients who developed AKI per the International Ascites Club 2015 definition (419 with maximum stage 1 and 341 with maximum stage 2 or 3; 63% male; mean age, 58 y). We compared demographic features, laboratory values, AKI treatment response, and survival between patients with maximum stage 1 vs patients with stage 2 or 3 AKI. Patients with stage 2 or 3 AKI had higher Model for End-Stage Liver Disease scores (25.9 ± 7.3) than patients with stage 1 AKI (21.9 ± 7.5) (P < .0001). More patients fulfilled systemic inflammatory response syndrome criteria on admission, and more developed a second nosocomial infection (P < .05 for both comparisons). More patients with stage 2 or 3 AKI also had progression of AKI and required dialysis and admission into intensive care units when compared to stage 1 AKI patients (P < .0001 for both). A lower proportion of patients with stage 2 or 3 AKI survived their hospital stay (80% vs 99% with stage 1 AKI; P < .0001), or survived for 30 days without a liver transplant (56% vs 81%; P < .0001). The development of stage 2 or 3 AKI was associated with a higher Model for End-Stage Liver Disease score at the time of admission (P < .0001), presence of systemic inflammatory response on admission (P = .039), and second infection (P < .0001). Based on an analysis of data from the North American Consortium for the Study of End-stage Liver Disease cohort, we found that patients with cirrhosis and more advanced liver disease, as well as a second infection, are more likely to develop stages 2 or 3 AKI, with a progressive course associated with decreased 30-day transplant-free survival. Prevention of AKI progression in patients with cirrhosis and stage 2 or 3 AKI might improve their outcomes." @default.
• W3048690244 created "2020-08-18" @default.
• W3048690244 creator A5005194886 @default.
• W3048690244 creator A5012239800 @default.
• W3048690244 creator A5012827359 @default.
• W3048690244 creator A5014267368 @default.
• W3048690244 creator A5018974631 @default.
• W3048690244 creator A5037020880 @default.
• W3048690244 creator A5037131547 @default.
• W3048690244 creator A5039066540 @default.
• W3048690244 creator A5048547936 @default.
• W3048690244 creator A5058513233 @default.
• W3048690244 creator A5059337045 @default.
• W3048690244 creator A5060196987 @default.
• W3048690244 creator A5064394293 @default.
• W3048690244 creator A5067770887 @default.
• W3048690244 creator A5076488821 @default.
• W3048690244 date "2021-08-01" @default.
• W3048690244 modified "2023-10-18" @default.
• W3048690244 title "Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites" @default.
• W3048690244 cites W1577539926 @default.
• W3048690244 cites W1585049907 @default.
• W3048690244 cites W1899691766 @default.
• W3048690244 cites W1981363992 @default.
• W3048690244 cites W1989492547 @default.
• W3048690244 cites W1998643708 @default.
• W3048690244 cites W2022358118 @default.
• W3048690244 cites W2035840561 @default.
• W3048690244 cites W2036639404 @default.
• W3048690244 cites W2053554521 @default.
• W3048690244 cites W2077014158 @default.
• W3048690244 cites W2094598763 @default.
• W3048690244 cites W2128580418 @default.
• W3048690244 cites W2135617792 @default.
• W3048690244 cites W2144416322 @default.
• W3048690244 cites W2148308926 @default.
• W3048690244 cites W2178421940 @default.
• W3048690244 cites W2516525156 @default.
• W3048690244 cites W2529083555 @default.
• W3048690244 cites W2542727939 @default.
• W3048690244 cites W2603952611 @default.
• W3048690244 cites W2608770331 @default.
• W3048690244 cites W2783787964 @default.
• W3048690244 cites W2790178929 @default.
• W3048690244 cites W2803015713 @default.
• W3048690244 cites W2888873829 @default.
• W3048690244 cites W2907608712 @default.
• W3048690244 cites W2923370329 @default.
• W3048690244 cites W2961463153 @default.
• W3048690244 doi "https://doi.org/10.1016/j.cgh.2020.08.025" @default.
• W3048690244 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32798707" @default.
• W3048690244 hasPublicationYear "2021" @default.
• W3048690244 type Work @default.
• W3048690244 sameAs 3048690244 @default.
• W3048690244 citedByCount "12" @default.
• W3048690244 countsByYear W30486902442021 @default.
• W3048690244 countsByYear W30486902442022 @default.
• W3048690244 countsByYear W30486902442023 @default.
• W3048690244 crossrefType "journal-article" @default.
• W3048690244 hasAuthorship W3048690244A5005194886 @default.
• W3048690244 hasAuthorship W3048690244A5012239800 @default.
• W3048690244 hasAuthorship W3048690244A5012827359 @default.
• W3048690244 hasAuthorship W3048690244A5014267368 @default.
• W3048690244 hasAuthorship W3048690244A5018974631 @default.
• W3048690244 hasAuthorship W3048690244A5037020880 @default.
• W3048690244 hasAuthorship W3048690244A5037131547 @default.
• W3048690244 hasAuthorship W3048690244A5039066540 @default.
• W3048690244 hasAuthorship W3048690244A5048547936 @default.
• W3048690244 hasAuthorship W3048690244A5058513233 @default.
• W3048690244 hasAuthorship W3048690244A5059337045 @default.
• W3048690244 hasAuthorship W3048690244A5060196987 @default.
• W3048690244 hasAuthorship W3048690244A5064394293 @default.
• W3048690244 hasAuthorship W3048690244A5067770887 @default.
• W3048690244 hasAuthorship W3048690244A5076488821 @default.
• W3048690244 hasBestOaLocation W30486902441 @default.
• W3048690244 hasConcept C126322002 @default.
• W3048690244 hasConcept C146357865 @default.
• W3048690244 hasConcept C151730666 @default.
• W3048690244 hasConcept C2776988256 @default.
• W3048690244 hasConcept C2777075537 @default.
• W3048690244 hasConcept C2777214474 @default.
• W3048690244 hasConcept C2779250428 @default.
• W3048690244 hasConcept C2779609443 @default.
• W3048690244 hasConcept C2779978075 @default.
• W3048690244 hasConcept C2780472472 @default.
• W3048690244 hasConcept C2780496750 @default.
• W3048690244 hasConcept C2911091166 @default.
• W3048690244 hasConcept C71924100 @default.
• W3048690244 hasConcept C86803240 @default.
• W3048690244 hasConcept C90924648 @default.
• W3048690244 hasConceptScore W3048690244C126322002 @default.
• W3048690244 hasConceptScore W3048690244C146357865 @default.
• W3048690244 hasConceptScore W3048690244C151730666 @default.
• W3048690244 hasConceptScore W3048690244C2776988256 @default.
• W3048690244 hasConceptScore W3048690244C2777075537 @default.
• W3048690244 hasConceptScore W3048690244C2777214474 @default.
• W3048690244 hasConceptScore W3048690244C2779250428 @default.
• W3048690244 hasConceptScore W3048690244C2779609443 @default.

• next